These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32683457)

  • 41. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
    McMahon CM; Perl AE
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
    [No Abstract]   [Full Text] [Related]  

  • 42. Glasdegib: First Global Approval.
    Hoy SM
    Drugs; 2019 Feb; 79(2):207-213. PubMed ID: 30666593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
    Galinsky I; Coleman M; Fechter L
    Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
    Goldsmith SR; Lovell AR; Schroeder MA
    Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang ES
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incorporating newer agents in the treatment of acute myeloid leukemia.
    Raj RV; Abedin SM; Atallah E
    Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel Therapies in Acute Myeloid Leukemia.
    Mukherjee S; Sekeres MA
    Semin Oncol Nurs; 2019 Dec; 35(6):150955. PubMed ID: 31759818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
    Mukherjee D; Brackman DJ; Suleiman AA; Zha J; Menon RM; Salem AH
    J Clin Pharmacol; 2023 Jan; 63(1):119-125. PubMed ID: 35996877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
    Solana-Altabella A; Megías-Vericat JE; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):133-148. PubMed ID: 36708283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
    Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
    J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
    Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
    Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute myeloid leukemia transformed to a targetable disease.
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
    Martínez-Cuadrón D; Rodríguez-Macías G; Rodríguez-Veiga R; Boluda B; Montesinos P
    Clin Drug Investig; 2020 Mar; 40(3):227-235. PubMed ID: 31912423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.
    de Leeuw DC; Ossenkoppele GJ; Janssen JJWM
    Curr Oncol Rep; 2022 Nov; 24(11):1387-1400. PubMed ID: 35653050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
    Janus SE; Heisler AC; Al Jammal M; Chahine N; Chami T; Hajjari J; Mously H; Badhwar A; Arora S; Al-Juhaishi T; Al-Kindi SG; Hoit BD
    Curr Probl Cardiol; 2022 Nov; 47(11):101345. PubMed ID: 35948197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.